AmpliPhi Biosciences Corp. (APHB)

3.10
0.05 1.64
AMEX : Health Technology
Prev Close 3.05
Open 3.15
Day Low/High 2.94 / 3.15
52 Wk Low/High 2.15 / 19.18
Volume 14.08K
Avg Volume 1.02M
Exchange AMEX
Shares Outstanding 33.47M
Market Cap 10.64M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
AmpliPhi Biosciences Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort

AmpliPhi Biosciences Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today provided an update on the progress of its ongoing...

AmpliPhi Biosciences Terminates Collaboration Agreement With Intrexon

AmpliPhi Biosciences Terminates Collaboration Agreement With Intrexon

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has provided written notice to...

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, presented data at the European Congress of Clinical...

AmpliPhi Biosciences Announces Conversion Of All Series B Redeemable Preferred Stock Into Common Stock

AmpliPhi Biosciences Announces Conversion Of All Series B Redeemable Preferred Stock Into Common Stock

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that all 7.

AmpliPhi Biosciences Reports Full-Year 2015 Financial Results

AmpliPhi Biosciences Reports Full-Year 2015 Financial Results

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the fiscal year ended...

AmpliPhi Biosciences To Host Full-Year 2015 Financial Results Conference Call And Webcast On March 30, 2016

AmpliPhi Biosciences To Host Full-Year 2015 Financial Results Conference Call And Webcast On March 30, 2016

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it will report financial results for the...

AmpliPhi Biosciences CEO To Present At 28th Annual ROTH Conference

AmpliPhi Biosciences CEO To Present At 28th Annual ROTH Conference

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that M.

AmpliPhi Biosciences Announces Award Of Federal Research Grant From Australia To Its Collaboration Partner, Westmead Institute

AmpliPhi Biosciences Announces Award Of Federal Research Grant From Australia To Its Collaboration Partner, Westmead Institute

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, congratulates the Westmead Institute's Centre for Infectious...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

AmpliPhi Biosciences Announces Dosing Of First Patient In Phase 1 Clinical Trial Of AB-SA01

AmpliPhi Biosciences Announces Dosing Of First Patient In Phase 1 Clinical Trial Of AB-SA01

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announces it has dosed the first patient in its Phase 1...

AmpliPhi Biosciences Announces Appointment Of Steve R. Martin As Chief Financial Officer

AmpliPhi Biosciences Announces Appointment Of Steve R. Martin As Chief Financial Officer

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Steve R.

AmpliPhi Acquires Key Bacteriophage Assets From UK-based Novolytics

AmpliPhi Acquires Key Bacteriophage Assets From UK-based Novolytics

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced it has acquired key assets from UK-based...

AmpliPhi Signs Clinical Trial Agreement With University Of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections

AmpliPhi Signs Clinical Trial Agreement With University Of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections

AmpliPhi Biosciences Corporation (NYSEMKT:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that it has entered into a Clinical...

AmpliPhi Announces Board Expansion With Appointment Of Two Highly-Experienced Non-Executive Directors

AmpliPhi Announces Board Expansion With Appointment Of Two Highly-Experienced Non-Executive Directors

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced that Vijay B.

AmpliPhi's Chief Executive Officer, M. Scott Salka, Gives Interview To The Wall Street Transcript

AmpliPhi's Chief Executive Officer, M. Scott Salka, Gives Interview To The Wall Street Transcript

M. Scott Salka, the Chief Executive Officer of AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a biotechnology company focused on the discovery, development and commercialization of novel bacteriophage therapeutics,...

AmpliPhi Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model

AmpliPhi Announces Data Demonstrating Efficacy Of A Novel Bacteriophage Cocktail Is Comparable To Vancomycin In S. Aureus Lung Infection Model

AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced experimental results highlighting that...

AmpliPhi Biosciences To Present At Rodman & Renshaw 17th Annual Global Investment Conference

AmpliPhi Biosciences To Present At Rodman & Renshaw 17th Annual Global Investment Conference

AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M.

AmpliPhi Biosciences Announces Appointment Of Alexander Gaidamaka As Vice President Of Chemistry, Manufacturing And Control

AmpliPhi Biosciences Announces Appointment Of Alexander Gaidamaka As Vice President Of Chemistry, Manufacturing And Control

AmpliPhi Biosciences Corporation (NYSE: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that Alexander Gaidamaka, Ph.

AmpliPhi To Present At The 21st Biennial Evergreen International Phage Meeting

AmpliPhi To Present At The 21st Biennial Evergreen International Phage Meeting

AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, announced that the Company will give a presentation today...

AmpliPhi BioSciences Cleared To Submit Listing Application To NYSE MKT

AmpliPhi BioSciences Cleared To Submit Listing Application To NYSE MKT

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a...

AmpliPhi To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015

AmpliPhi To Present Research On Efficacy Of A Novel Bacteriophage Cocktail In S. Aureus Lung Infection Model At ICAAC/ICC 2015

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that data comparing the efficacy of its...

AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization

AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that...

AmpliPhi To Present New Data On Biological Activity Of Nebulized Anti-Pseudomonal Bacteriophage

AmpliPhi To Present New Data On Biological Activity Of Nebulized Anti-Pseudomonal Bacteriophage

AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P.

AmpliPhi's Bacteriophage Manufacturing Facility Receives CGMP Certification

AmpliPhi's Bacteriophage Manufacturing Facility Receives CGMP Certification

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that its production facility in Ljubljana,...

AmpliPhi Provides Corporate Update And Reports First Quarter 2015 Financial Results

AmpliPhi Provides Corporate Update And Reports First Quarter 2015 Financial Results

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today provided a corporate update and announced financial...

New CEO Of AmpliPhi BioSciences, M. Scott Salka (Photo: Business Wire)

New CEO Of AmpliPhi BioSciences, M. Scott Salka (Photo: Business Wire)

AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that M.

AmpliPhi Granted European Patent For Bacteriophage Therapy To Fight Biofilm-related Bacterial Infections

AmpliPhi Granted European Patent For Bacteriophage Therapy To Fight Biofilm-related Bacterial Infections

AmpliPhi BioSciences Corporation (OTCQB:APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has...

AmpliPhi BioSciences Corporation Announces $13 Million Financing

AmpliPhi BioSciences Corporation Announces $13 Million Financing

AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of...

AmpliPhi Provides Shareholder Update

AmpliPhi Provides Shareholder Update

AmpliPhi BioSciences Corporation (OTCQB: APHB), the global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, provided an update to shareholders during a...

AmpliPhi BioSciences To Host Shareholder Update Conference Call

AmpliPhi BioSciences To Host Shareholder Update Conference Call

AmpliPhi BioSciences Corporation (OTCQB:APHB) ("AmpliPhi"), the leader in the discovery and development of bacteriophage based therapies to treat drug resistant bacterial infections, today announced that it will host a...